New Data, New Directions: Neladalkib (NVL-655) and Precision Oncology in ALK-positive Cancer Alexander Drilon, MD, is a thoracic oncologist and Chief of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center, including research focused on ALK-positive cancers. Sunday, March 1st at 7:00pm ET, Alexander Drilon, MD joins ALKtALK to present and discuss the latest data […]

